Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine

Clinical Cancer Research

Volumn 12, Issue 1, 2006, Pages 214-222

  Haas, Andrew R ^a   Sun, Jing ^a   Vachani, Anil ^a   Wallace, Africa F ^a   Silverberg, Michael ^a   Kapoor, Veena ^a   Albelda, Steven M ^a  

^a Thoracic Oncology Research Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; CYCLOOXYGENASE 2 INHIBITOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; MESSENGER RNA; PROTEIN E7; ROFECOXIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL STRAIN TC1; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; ENZYME INHIBITION; FLOW CYTOMETRY; GENE THERAPY; IMMUNOGENETICS; LYMPH NODE; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; VACCINATION;

ADMINISTRATION, ORAL; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CYCLOOXYGENASE 2 INHIBITORS; FLOW CYTOMETRY; HUMANS; LACTONES; MICE; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONES;

EID: 31544477761     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1178     Document Type: Article

References (44)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
2. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 2004;4:401-11.
3. Berzofsky JA, Terabe M, Oh S, et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004;113:1515-25.
4. Henderson RA, Mossman S, Nairn N, et al. Cancer vaccines and immunotherapies: emerging perspectives. Vaccine 2005;23:2359-62.
5. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807-39.
6. Akhurst RJ, Derynck R. TGF-β signaling in cancer-a double-edged sword. Trends Cell Biol 2001;11: S44-51.
7. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother 2001;24:392-407.
8. Mocellin S, Rossi CR, Nitti D. Cancer vaccine development: on the way to break immune tolerance to malignant cells. Exp Cell Res 2004;299:267-78.
9. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611-8.
10. Lee KM, Chuang E, Griffin M, et al. Molecular basis of T cell inactivation by CTLA-4. Science 1998;282:2263-6
11. Terabe M, Berzofsky JA. Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 2004;16:157-62.
12. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-8.
13. Serafini P, De Santo C, Marigo I, et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004;53:64-72.
14. Pasche B. Role of transforming growth factor β in cancer. J Cell Physiol 2001;186:153-68.
15. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001;23:263-72.
16. Rodriguez PC, Quiceno DG, Zabaleta J, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004;64:5839-49.
17. Seo N, Hayakawa S, Takigawa M, et al. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology 2001;103:449-57.
18. Harris SG, Padilla J, Koumas L, et al. Prostaglandins as modulators of immunity. Trends Immunol 2002;23:144-50.
19. Yang L, Yamagata N, Yadav R, et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 2003;111:727-35.
20. 2-treated human T lymphocytes, Immunopharmacol Immunotoxicol 2000;22:117-29.
21. 2+ mobilization in T cells. Am J Physiol 1999;277:R1741-8.
22. Choudhry MA, Ahmed Z, Sayeed MM. PGE(2)-mediated inhibition of T cell p59(fyn) is independent of cAMP. Am J Physiol 1999;277:C302-9.
23. Hilkens CM, Snijders A, Snijdewint FG, et al. Modulation of T-cell cytokine secretion by accessory cell-derived products. Eur Respir J Suppl 1996;22:90-4s.
24. 2, promote Th2 responses. Adv Exp Med Biol 1997;417:363-7.
25. Harizi H, Juzan M, Grosset C, et al. Dendritic cells issued in vitro from bone marrow produce PGE(2) that contributes to the immunomodulation induced by antigen-presenting cells. Cell Immunol 2001;209:19-28.
26. Harizi H, Juzan M, Pitard V, et al. Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol 2002;168:2255-63.
27. + T regulatory cell activities in lung cancer. Cancer Res 2005;65:5211-20.
28. De Long P, Tanaka T, Kruklitis R, et al. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res 2003;63:7845-52.
29. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6.
30. He Z, Wlazlo AP, Kowalczyk DW, et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 2000;270:146-61.
31. Oehen S, Brduscha-Riem K. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J Immunol 1998;161:5338-46.
32. Tanaka T, Delong PA, Amin K, et al. Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery. Ann Surg 2005;241:168-78.
33. Morelli AE, Thomson AW. Dendritic cells under the spell of prostaglandins. Trends Immunol 2003;24:108-11.
34. Sharma S, Stolina M, Yang SC, et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 2003;9:961-8.
35. Wlazlo AP, Deng H, Giles-Davis W, et al. DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins. Cancer Gene Ther 2004;11:457-64.
36. Ahn WS, Bae SM, Kim TY, et al. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Hum Gene Ther 2003;14:1389-99.
37. Tillman BW, Hayes TL, DeGruijl TD, et al. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res 2000;60:5456-63.
38. Gunn GR, Zubair A, Peters C, et al. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 2001;167:6471-9.
39. Youde SJ, Dunbar PR, Evans EM, et al. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Res 2000;60:365-71.
40. Daemen T, Riezebos-Brilman A, Regts J, et al. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Amivir Ther 2004;9:733-42.
41. Sharma S, Zhu L, Yang SC, et al. Cyclooxygenase 2 inhibition promotes IFN-γ-dependent enhancement of antitumor responses. J Immunol 2005;175:813-9.
42. Zeytin HE. Patel AC, Rogers CJ, et al. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA. Tg/MIN mice. Cancer Res 2004;64:3668-78.
43. Stolina M, Sharma S, Lin Y et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000;164:361-70.
44. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58:1208-16.